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Pediatric NHLAbstract Aim of work: To evaluate the sensitivity (Se), specificity (Sp), and predictive values (PV)
of PET scan during management of pediatric mature B cell non-Hodgkin’s lymphoma (NHL) in
comparison with conventional computed tomography (CT) scan.
Patients and methods: A retrospective study enrolled on pediatric NHL patients at Children Cancer
Hospital Egypt (CCHE) during the period from July 2007 to the end of June 2013.
Results: For 115 pediatric patients diagnosed with mature B cell NHL, 152 PET and 152 CT scans
were done simultaneously. Median age was 5.7 years. They were 85 males (74%) and 30 females
(26%). One hundred twenty six scans (82.9%) were done for 100 (87%) Burkitt lymphoma (BL)
patients, while 26 scans (17.1%) were done for 15 (13.0%) patients with diffuse large B cell
NHL (DLBC). Nineteen examination (12.5%) were done before starting chemotherapy (group
1), 107 (70.3%) at time of evaluation (group 2), and 26 (17.1%) during follow up (group C). Overall
sensitivity was 91.6% for PET and 70.0% for conventional CT (p= 0.02). Specificity was 84.1%
for PET and 58.9% for CT (p< 0.001). Positive predictive value (PPV) for PET was 50%, while
was 22% for CT scan (p< 0.001). Negative predictive value (NPV) for PET was 98%, and 92%
for CT (p= 0.01).l Egypt.
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Pediatric mature B-cell non-Hodgkin lymphomas (NHL) are
highly aggressive malignant tumors. Over the past 25 years,
multidisciplinary pediatric cooperative group collaborations
have reported 99% overall survival rate in low risk patients,
90% in intermediate-risk, and a 70% to 80% in children with
high risk [1–3].
Evaluation of residual masses in cases of incomplete remis-
sion is one of the major difficulties during treatment. More-
over, pathologic documentation may hold unnecessary risks
[4–7].
18-F-fluorodeoxyglucose (FDG)-positron emission tomog-
raphy (PET) is a noninvasive, 3-dimensional imaging modality
that has become widely used in the management of adults with
malignant lymphomas. Current applications may include pre-
treatment staging, restaging, monitoring of therapy effect, and
follow up (FU) [8–10]. However, only a few experiences have
been reported in children with mature B cell NHL [11–13],
with unsettled utility for response assessment [14–15].
The aim of the current study is to evaluate the sensitivity
(Se), specificity (Sp), and predictive values (PV) of PET scan
compared to conventional CT scan. In addition, we wanted
to test the reliability of such a non invasive tool during man-
agement of pediatric mature B cell NHL, and its impact on
the decision whether or not a biopsy should be taken.
Patients and methods
It is a retrospective study enrolled on newly diagnosed
pediatric NHL patients treated at the Children Cancer Hospital
Egypt (CCHE) during the period from July 2007 to the end of
June 2013. Inclusion criteria were PET – in addition to
conventional CT scan – done at any stage of the treatment.
Blind revision of all PET and CT scans was specifically done
for this study.
This study included 115 patients for whom 152 PET scan –
in addition to conventional CT scan – was done at any stage of
the treatment. All patients were treated and assessed according
to the LMB 96 treatment protocol [16]. Staging was performed
according to Murphy’s classification [17]. Tumor resection
and/or biopsy outside CCHE were not an exclusion criterion.
Initial evaluation included clinical, and laboratory diagnostic
workup. Written informed consent was obtained from each
patient’s parents. The local ethics committee approved this
study. The end point used for final evaluation is the final clin-
ical outcome at the end of the follow up period. Patients were
followed up till 01/03/2014.
Conventional imaging
Tumor assessment was done using computed tomography
(CT) with contrast (Sensation 16, Siemens; Light Speed
VCT, GE Medical Systems). In cases with head and neckinvolvement or suspected meningeal infiltration, MRI was per-
formed. All CT images were evaluated based on 1999 interna-
tional workshop criteria (IWC) [5]. Radiological films were
evaluated by two experienced pediatric radiologists blinded
to the PET results specifically for the aim of the study. CT scan
was used for initial evaluation, during treatment evaluation
and follow up.18FDG-PET procedure
The use of standardized uptake values (SUVs) of the radiola-
beled tracer 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has a
specific role in assessing patient response to therapy since
increased accumulation of FDG relative to normal tissue is a
useful marker [18]. Measuring methods of the rate of accumu-
lation by [kBq/ml] reflects the relative tissue uptake of FDG.
So the standardized uptake value (SUV) is commonly used
as a relative measure of FDG uptake [19]. Whole-body
18FDG-PET was acquired on a Discovery LS PET/CT imag-
ing system (GE Medical Systems) 60–80 min after intravenous
injection of 5–7 MBq/kg of 18FDG or on a mCT Biograph
imaging system (Siemens) after intravenous injection of
3 MBq/kg of 18FDG. Children fasted at least 4 h before
18FDG injection and blood glucose was controlled prior to
the injection. Images were reconstructed by OSEM iterative
reconstruction algorithm (ordered-subset expectation maxi-
mization) with and without attenuation correction. All
18FDG-PET images were retrospectively reviewed on a dedi-
cated workstation (Positoscope; Keosys, France). 18FDG-
PET was interpreted visually by at least two nuclear medicine
physicians with expertise in lymphoma imaging using the five-
point scale (Deauville criteria), as recently recommended by
Lugano’s recommendations in lymphoma [4].18FDG-PET analysis
In addition to the standard procedures, whole-body 18FDG-
PET was done for those patients. According to timing of the
PET exam, patients were divided into 3 groups: group 1:
PET done before starting chemotherapy, group 2: PET done
to evaluate chemotherapy response according to treatment
protocol (after 3 and 4 courses of chemotherapy for intermedi-
ate risk and high risk groups respectively), and group 3: PET
done during follow up (FU) period (Fig. 1).Statistical methods
The diagnostic performance of PET scan was estimated by cal-
culating its sensitivity (Se), specificity (Sp), positive predictive
value (PPV), and negative predictive value (NPV) in relation
to that of conventional radiology. Results were classified as
true positive or negative, and false positive or negative sup-
ported by the status of the disease.
Assessment  per group of patients 
Gp 1 n = 19 Gp 2  n = 106 Gp 3 n = 28
Prior to chemotherapy Time of evaluation                 Follow up
Figure 1 Patient grouping according to time of PET examina-
tion. Group 1: examination done prior to start of chemotherapy.
Group 2: PET done at the time of evaluation according to the
treatment protocol to assess tumor response to chemotherapy.
Group 3: PET done after the end of chemotherapy as to document
relapse.
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Paired-sample specificity analysis
A sample size of 152 achieves 86% power to detect a difference
of 0.27 between two diagnostic tests whose specificities are 0.85
and 0.58 [20]. This procedure uses a two-sided McNemar test
with a significance level of 0.05000 [21]. The prevalence of dis-
ease in the population is 0.25. The proportion of discordant
pairs is 0.32 [20,22–25].
Paired-sample sensitivity analysis
A sample size of 152 achieves 82% power to detect a difference
of 0.26 between two diagnostic tests whose sensitivities are 0.89
and 0.63 [20]. This procedure uses a two-sided McNemar test
with a significance level of 0.05 [21]. The prevalence of disease
in the population is 0.25. The proportion of discordant pairs is
0.32 [20,22–25].
The lesions found on FDG-PET/CT and CT scans were
compared. The concordance rate is defined as the number of
lesions seen by both modalities divided by the number of
lesions seen by at least one of the modalities. McNemar’s test
which is based on identifying the non-concordant lesions was
used to compare the two modalities. All reported p values
are based on this test.
Results
This study included 115 mature B cell NHL patients who
underwent 152 scan during the period from 7/7/2007 to
31/12/2013. Median duration of follow up was 42 months,
and ranged from 2 to 74 months.
Median age was 5.7 years (range 1–18 years). They were 85
males (74%) and 30 females (26%). One hundred Burkitt lym-
phoma patients (87%) underwent 126 PET scans (83.0%),
while fifteen patients (13%) had diffuse large B cell (DLBL),
and did 26 PET (17.0%).
In group 1; 19 PET scans (16.5%) were done before starting
chemotherapy. Sixteen (84.2%) post surgical resection of
intestinal mass (stage II disease), while the rest 3/19 (15.8%)
as initial work up. For 8/19 (42%), PET confirmed the absence
of residual disease, and patients were treated as low risk (LR).In 8/19 (42%), PET detected post operative residual tumor
mass, and patients were upgraded to intermediate risk group.
In group 2; 107 PET (69.2%) were done at the time of re-
evaluation of chemotherapy response. PET and CT were con-
cordant in 67/107 (62.6%), and disconcordant in 40/107
(37.4%) of cases respectively. In disconcordant cases, PET
was true negative in 35/40 cases (87.5%), false positive in
3/40 cases (7.5%), and true positive in 2/38 case (5%), with
no false negative results.
In group 3, 26 PET (18.3%) were done during follow up.
PET and CT were concordant in 20/26 (77%) of the cases,
and disconcordant in 6/26 (23%). PET was true negative in
3/6 cases (50%), false positive in 2 cases (33%), true positive
in one case (17%), and no false negative.
Overall, sensitivity was 89.4% for PET, and 63.1% for CT
(p= 0.02). Specificity was 84.9% for PET, and 58.6% for CT
(p< 0.001). PPV for PET was 45.9%, while was 17.9% for CT
scan (p< 0.001). NPV for PET was 98.2%, while was 91.7%
for CT (p= 0.01).
In BL, sensitivity was 91.6% for PET, and 66.6% for CT
(p= 0.08). Specificity was 85.8% for PET, while was 58.4%
for CT (p< 0.001). PPV and NPV were 40.7% and 98.9%,
for PET, while were 14.5% and 94.2% for CT scan
(p< 0.001, and 0.05 respectively).
In DLBC, sensitivity was 85.7% for PET while was 57.1%
for CT (p= 0.15). Specificity was 80.0% for PET, while was
60.0% for CT (p< 0.20). PPV and NPV for PET were
60.0%, and 94.1% respectively, while were 33.3% and
80.0% for CT scan (p< 0.07, and 0.10) respectively (Table 1).
Discussion
This retrospective study was conducted in the Children Cancer
Hospital Egypt. The main objective was to determine the role,
and impact of 18FDG-PET done during the course of
chemotherapy and FU period on the physician decision to
go for pathological documentation. Mature B cell NHL tends
to relapse very early (within the first 6 months after end of
treatment) [16]. The median duration of FU was 42 months
(range 2–74 months). Our cutoff value was the patient final
clinical outcome.
Assessment of response to chemotherapy with CT scans
alone has its drawbacks. It lacks functional information and
detection of lesions is poor contrast with the surrounding tis-
sue [25]. As previously mentioned by many authors, the pres-
ence of residual mass by CT scan at time of evaluation
during the course of chemotherapy poses many difficulties.
Surgical or radiological documentation of viable tissue is
sometimes difficult, invasive, and may pose unnecessary risks
[4–7]. Functional imaging with PET scanning, explained by
the superadded role of biological assessment through measur-
ing the FDG uptake by the viable lymphomatous tissue, may
help to resolve this dilemma [26]. Studies have proven its accu-
racy staging, restaging and as a prognostic indicator for the
treatment outcome [27–30]. In the current study, PET done
before stating chemotherapy excluded the presence of residual
disease in 7% of the patients, and lead to their restratification
as LR. They were all alive in CR by the end of the study. Mean-
while another 7% were upgraded to IR group as they had PET
evidence of residual disease. The use of FDG-PET/CT resulted
Table 1 Sensitivity, specificity, PPV, NPV and confidence interval of the studied patients.
Results All scans (n= 152) BL (n= 126) DLBC (n= 26)
PET CT p PET CT p PET CT p
Sensitivity 89.5% 63.2% 0.0253 91.7% 66.7% 0.083 85.7% 57.1% 0.157
(75.7%-99%) (41.5–84.8) (76–100) (40–93.3) (59.8–100) (20.5–93.8)
Specificity 84.9% 58.6% <0.001 85.8% 58.4% <0.001 80.0% 60.0% 0.205
(78.9–91%) (50.3–67) (79.4–92.3) (49.3–67.5) (62.5–97.5) (38.3–81.5)
PPV 45.9% 17.9% <0.001 40.7% 14.5% <0.001 60.0% 33.3% 0.075
(29.9–62%) (8.7–27.1) (22.2–59.3) (5.2–23.9) (29.6–90.4) (6.7–60)
NPV 98.3% 91.7% 0.011 98.9% 94.3% 0.054 94.1% 80.0% 0.101
(95.9–99.9%) (85.9–97.6) (97–100%) (88.8–99.7) (82.9–100) (59.8–100)
BL: Burkitt lymphoma, CI: confidence interval, DLBC: diffuse large B cell, NPV: negative predictive value, PPV: positive predictive value.
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CT [31].
In group 2 and 3 patients (those who had PET at time of
evaluation, or during FU), PET was very good negative test
despite the presence of a radiologically evident residual mass.
PET and CT were disconcordant in 37.4% and 23% in group
2 and 3 patients respectively, but only 11.3% of the patient did
a biopsy. In the current study, biopsy was positive only
patients were both tools were positive. In our study, PET
has a statistically significant higher sensitivity, specificity,
and more importantly, nearly no false negative results.
PPV for PET was 40.7%, compared to 14.5% for CT scan
(p< 0.001), indicating a considerable number of false positive
results when using conventional CT. This could be explained
by the presence of non viable fibrotic residue falsely taken as
a positive test. We could depend with confidence on PET in
confirming true negative results.
CT scan has a relatively high sensitivity and specificity for
pretreatment staging of lymphoma. The high frequency of
residual masses present in cases with initially bulky disease
affects its specificity for post-treatment evaluation [32–35].
PET CT is not recommended in routine follow up after com-
plete remission. It has a low PPV due to post therapeutic
inflammation taken denoting high false positivity rather than
true relapse [4]. Our study weakness is being a retrospective
one, were different radiological assessment, and at different
stages of disease. Further data on the significance of a PET
CT at presentation, and time of evaluation in children with
NHL is needed to better assess its role as a reliable tool for
evaluation of response.Conclusion and recommendations
PET scan is significantly more sensitive than conventional CT
in the management of aggressive pediatric mature B cell NHL.
It remains a good negative test. Further prospective study is
needed to assess the reliability of such a tool in mature B cell
lymphoma subtypes.Conflict of interest
None declared.References
[1] Atra A, Imeson JD, Hobson R, Gerrard M, Hann IM, Eden
OB, et al. Improved outcome in children with advanced stage B-
cell non-Hodgkin’s lymphoma (B-NHL): results of the United
Kingdom children’s cancer study group (UKCCSG) 9002
protocol. Br J Cancer 2000;82(8):1396–402.
[2] Cairo MS, Sposto M, Hoover-Regan M, Meadows AT,
Anderson JR, Siegel SE, et al. Childhood and adolescent
large-cell lymphoma (LCL): a review of the children’s cancer
group experience. Am J Hematol 2003;72:53–63.
[3] Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan
ML, Anderson JR, et al. Burkitt’s and Burkitt-like lymphoma in
children and adolescents: a review of the children’s cancer group
experience. Br J Haematol 2003;120(4):660–70.
[4] Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH,
Zucca E, et al. Recommendations for initial evaluation, staging,
and response assessment of Hodgkin and non-Hodgkin
lymphoma: the Lugano classification. J Clin Oncol
2014;32:3059–67.
[5] Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M,
Hutchings M, Mu¨eller SP, et al. Role of imaging in the staging
and response assessment of lymphoma: consensus of the
international conference on malignant lymphomas imaging
working group. J Clin Oncol 2014;32:3048–58.
[6] Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A,
et al. Prognostic value of interim 18F-FDG PET in patients with
diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles
of chemotherapy. J Nucl Med 2009;50:527–33.
[7] Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto
R, et al. Results of the randomized international FAB/LMB96
trial for intermediate risk B-cell non-Hodgkin lymphoma in
children and adolescents: it is possible to reduce treatment for
the early responding patients. Blood 2007;109(7):2773–80.
[8] Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi
A. F-18 FDG-PET imaging and correlation with CT in staging
and follow-up of pediatric lymphomas. Pediatr Radiol 2006;36
(6):524–31.
[9] Riad R, Omar W, Kotb M, Hafez M, Sidhom I, Zamzam M,
et al. Role of PET/CT in malignant pediatric lymphoma. Eur J
Nucl Med Mol Imaging 2010;37:319–29.
[10] Nakatani K, Nakamoto Y, Watanabe K, Saga T, Higashi T,
Togashi K. Roles and limitations of FDG PET in pediatric non-
Hodgkin lymphoma. Clin Nucl Med 2012;7:656–62.
[11] Sioka C. The utility of FDG PET in diagnosis and follow-up of
lymphoma in childhood. Eur J Pediatr 2013;172:733–8.
[12] Furth C, Steffen IG, Erdrich AS, Hundsdoerfer P, Ruf J, Henze
G, et al. Explorative analyses on the value of interim PET for
Management of pediatric mature B cell non-Hodgkin’s lymphoma 99prediction of response in pediatric and adolescent non-Hodgkin
lymphoma patients. EJNMMI Res. 2013;3:71.
[13] London K, Cross S, Onikul E, Dalla-Pozza L, Howman-Giles
R. 18F-FDG PET/CT in paediatric lymphoma: comparison
with conventional imaging. Eur J Nucl Med Mol Imaging
2011;38:274–84.
[14] Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P,
Biassoni L, et al. (18)F-FDG PET in pediatric lymphomas: a
comparison with conventional imaging. Cancer Biother
Radiopharm 2008;23:681–90.
[15] Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Thulkar S,
Vishnubhatla S, et al. Pediatric non lymphoblastic non-Hodgkin
lymphoma: baseline, interim, and posttreatment PET/CT versus
contrast- enhanced CT for evaluation – a prospective study.
Radiology 2012;262:956–68.
[16] Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC,
Harrison L, et al. Advanced stage, increased lactate
dehydrogenase, and primary Site, but not adolescent age
(15 years), are associated with an increased risk of treatment
failure in children and adolescents with mature B-Cell non-
Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin
Oncol 2012;30(4):387–93.
[17] Murphy SB. Classification, staging and results of treatment of
childhood non-Hodgkin’s lymphoma: dissimilarities from
lymphoma in adults. Semin Oncol 1980;7:332–9.
[18] Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA,
Cheng EY, et al. Progress and promise of FDG-PET imaging
for cancer patient management and oncologic drug
development. Clin Cancer Res 2005;11(8):2785–808.
[19] Thie JA. Understanding the standardized uptake value, its
methods, and implications for usage. J Nucl Med
2004;45:1431–4.
[20] Zhou XH, Obuchowski NA, McClish DK. Statistical methods
in diagnostic medicine. New York: Wiley-Interscience; 2002.
[21] Gerrard M, Waxman IM, Sposto R, Auperin A, Perkins SL,
Goldman S, et al. Outcome and pathologic classification of
children and adolescents with mediastinal large B-cell
lymphoma treated with FAB/LMB96 mature B-NHL therapy.
Blood 2013;121(2):278–85.
[22] Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E,
Frickhofen N, et al. Extranodal malignant lymphoma: detection
with FDG PET versus CT. Radiology 1998;206(2):475–81
[Internet].
[23] Li J, Fine J. On sample size for sensitivity and specificity in
prospective diagnostic accuracy studies. Stat Med
2004;23:2537–50.[24] Schork M, Williams G. Number of observations required for the
comparison of two correlated proportions. Commun Stat Simul
Comput 1980;B9(4):349–57.
[25] Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of
malignant lymphoma: a systematic review. Blood
2008;111:504–16.
[26] Karantanisa D, Durskia JM, Lowea VJ, Nathana MA, Mullana
BP, Georgioub E, et al. 18F-FDG PET and PET/CT in Burkitt’s
lymphoma. Eur J Radiol 2010;75:e68–73.
[27] Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A,
von Schulthess GK. Whole-body positron emission tomography
using fluorodeoxyglucose for staging of lymphoma: effectiveness
and comparison with computed tomography. Eur J Nucl Med
1998;25:721–8.
[28] Moog F, Kotzerke J, Reske SN. FDG PET can replace bone
scintigraphy in primary staging of malignant lymphoma. J Nucl
Med 1999;40:1407–13.
[29] Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM,
Dietlein M, Ali Guermazi A, et al. Use of positron emission
tomography for response assessment of lymphoma: consensus of
the imaging subcommittee of international harmonization
project in lymphoma. J Clin Oncol 2007;25:571–8.
[30] Freudenberg LS, Antoch G, Schu¨tt P, Beyer T, Jentzen W,
Mu¨ller SP, et al. FDG-PET/CT in re-staging of patients with
lymphoma. Eur J Nucl Med Mol Imaging 2004;31(3):325–9.
[31] Wafaie A, Kassem H, Kotb M, Zeitoun R, Ismail S. Evaluation
of the efficiency of FDG PET/CT in detection and
characterization of skeletal metastases. Egypt J Radiol Nucl
Med 2014;45:181–90.
[32] Schoder H, Noy A, Gonen Weng L, Green D, Erdi YE, et al.
Intensity of 18 fluorodeoxyglucose uptake in positron emission
tomography distinguishes between indolent and aggressive non-
Hodgkin’s lymphoma. J Clin Oncol 2005;23(21):4643–51.
[33] Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans
in patients with lymphoma. Blood 2007;110(10):3507–16.
[34] Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of
lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose:
correlation with CT. Radiology 1994;190(1):111–6.
[35] Surbone A, Longo DL, DeVita Jr VT, Ihde DC, Duffey PL,
Jaffe ES, et al. Residual abdominal masses in aggressive non-
Hodgkin’s lymphoma after combination chemotherapy:
significance and management. J Clin Oncol 1988;6:1832–7.
